Study finds eating disorder sufferers abuse diet pills, other OTC products
PHOENIX Between 11 million and 13 million people in the United States have eating disorders, and many of them abuse or become dependent upon over-the-counter substances, the Remuda Ranch Programs for Eating and Anxiety Disorders announced Wednesday.
“It may surprise many people, including some healthcare providers, that over-the-counter products and supplements for dieting purposes are frequently abused by those with eating disorders,” stated Kevin Wandler, spokesman for Remuda Ranch Programs for Eating and Anxiety Disorders. “A full 64% of eating disorder patients abuse diet pills. The health consequences of diet pill abuse are enormous and include high blood pressure, abnormal heart rhythms, tremors, thickening of the heart muscle and kidney damage.”
Other substances abused by individuals with eating disorders include laxatives and diuretics. Although laxatives and diuretics are not often considered drugs of abuse or dependence, individuals can become dependent on them. A recent study found that in a sample of 200 bulimics, 31% used diuretics.
“It can take the body months to recover from laxative and other over-the-counter substance abuse,” Wandler said.
As seen on shelf at Walgreens, having a major pharma player like Bayer HealthCare field what essentially is a hangover-relief product adds credibility, not to mention a little more shelf presence, to similar products like Living Essentials’ Chaser Plus.
XenaCare receives ‘Best New Product’ award at conference
DELRAY BEACH, Fla. XenaCare Holdings on Monday announced that its stage 2 pain reliever, Cobroxin, has won the award for “Best New Product,” sponsored by Drug Store News, at the recent ECRM Health held in Miami.
“It is an honor to have Cobroxin chosen as the best new product at ECRM,” stated Frank Rizzo, president of XenaCare. “This award … supports our belief that Cobroxin will soon become the preferred alternative to current opiate and acetaminophen-based analgesics,” he concluded.
Retailer attendees nominate and vote on “Best New Product” at the show.
Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Recently, XenaCare Holdings was awarded the exclusive license for marketing and distributing Cobroxin within the United States.
As part of Drug Store News’ sponsorship of the award, XenaCare Holdings will receive a full-page advertisement in an upcoming issue of Drug Store News.